Scholars Central

Short communicationPublished 15 Sep 2020

About Agile Sciences Inc

Authors: Malcolm Thomas

Journal of Pharmaceutical Microbiology

Volume 6 · Issue 3 · Pages 5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Agile Sciences, Inc. is a pre-clinical stage biopharmaceutical company based in Raleigh, North Carolina that is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections. The antibiotics market generated global sales of $39.6 billion in 2013. Despite this very large market, there are many infections that are not treatable by marketed antibiotics due to the growing issues of antibiotic resistance. These infections are responsible for an estimated 20,000 deaths in the United States each year with an associated $20 billion in direct health care costs and $35 billion in lost productivity. Antibiotic resistance is one the greatest health care challenges for the future, according to the World Health Organization. Despite this, very few new classes of antibiotics have been introduced over the past two decades due mainly to the early onset of resistance. Agile Sciences core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial resistance mechanisms through a novel mode of action, effectively rendering bacteria unable to protect themselves. These 2-AI compounds have been shown to: • Restore the activity of antibiotics against multi-drug resistant (MDR) Gram-positive and Gram-negative bacterial pathogens. • Reduce the dose of current antibiotics required to achieve bacterial clearance, sometimes by as much as 200-fold. • Mitigate the acquisition of antibiotic resistance • Inhibit and disperse bacterial communities, known as biofilms Agile Sciences’ 2-AI compounds have the potential to revitalize the antibiotic market by restoring drug resistant bacterial strains to many existing classes of antibiotics to address this large unmet medical need. The company’s primary focus is on treatment of Gram-negative MDR bacterial infections; along with treatment of lung infections in cystic fibrosis (CF) patients; and treatment of chronic wound infections.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutical Microbiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Microbiology
  • SubjectPharmaceutical Sciences
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Malcolm Thomas”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels